HALO240517P45000
- 0.18
- 0.000.00%
Halozyme Therapeutics Newsroom
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $50
H.C. Wainwright analyst Mitchell Kapoor maintains $Halozyme Therapeutics(HALO.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate o
Halozyme Therapeutics(HALO.US) Officer Sells US$905.48K in Common Stock
$Halozyme Therapeutics(HALO.US)$ Officer LaBarre Michael J. sold 20,000 shares of common stock on May 21, 22, 2024 at an average price of $45.274 for a total value of $905.48K.Source: Announcement Wha
Halozyme Therapeutics Insider Sold Shares Worth $905,480, According to a Recent SEC Filing
Michael J. Labarre, Senior Vice President, Chief Technical Officer, on May 21, 2024, sold 20,000 shares in Halozyme Therapeutics (HALO) for $905,480. Following the Form 4 filing with the SEC, Labarre
Form 144 | Halozyme Therapeutics(HALO.US) Officer Proposes to Sell 453.84K in Common Stocks
SEC FILLINGS DISCLOSED/ May 22, $Halozyme Therapeutics(HALO.US)$ Officer MICHAEL LABARRE intends to sell 10,000 shares of its common stock on May 22, with a total market value of approximately $453.84
Form 144 | Halozyme Therapeutics(HALO.US) Officer Proposes to Sell 451.64K in Common Stocks
SEC FILLINGS DISCLOSED/ May 21, $Halozyme Therapeutics(HALO.US)$ Officer MICHAEL LABARRE intends to sell 10,000 shares of its common stock on May 21, with a total market value of approximately $451.64
Halozyme Discloses That Bristol Myers Squibb Received Updated Action Date From U.S. FDA For Subcutaneous Nivolumab Co-Formulated With ENHANZE (Halozyme's Proprietary Recombinant Human Hyaluronidase Enzyme); The Updated Goal Date Is December 29, 2024
Halozyme announced that Bristol Myers Squibb was reassigned a Prescription Drug User Fee Act goal date from the U.S. Food and Drug Administration for their Biologics License Application for the subcut
Halo Capsule X Sets a New Benchmark in the Cordless Vacuum Market
BOCA RATON, Fla., May 13, 2024 /PRNewswire/ -- In response to the soaring demand for cordless vacuum cleaners in North America and Europe, driven by their convenience and support for busy lifestyles,
Halozyme Therapeutics Is Maintained at Market Outperform by JMP Securities
Halozyme Therapeutics Is Maintained at Market Outperform by JMP Securities
Halozyme Therapeutics Price Target Cut to $71.00/Share From $72.00 by JMP Securities
Halozyme Therapeutics Price Target Cut to $71.00/Share From $72.00 by JMP Securities
Express News | JMP Securities Maintains Market Outperform on Halozyme Therapeutics, Lowers Price Target to $71
Halozyme Therapeutics Currently Up Six Consecutive Days, On Track for Longest Winning Streak Since December 2022 -- Data Talk
Halozyme Therapeutics, Inc. (HALO) is currently at $43.10, up $1.89 or 4.59% --Would be highest close since Aug. 29, 2023, when it closed at $43.10 --On pace for largest percent increase since Feb.
Halozyme to Participate in Upcoming Investor Conferences
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present and...
Halozyme Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Halozyme Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Express News | HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $50 Price Target
Halozyme Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 19.33% HC Wainwright & Co. → $50 Reiterates Buy → Buy 05/07/2024 19.33% HC Wainwright & Co. → $
Express News | Halozyme Therapeutics Inc : Leerink Partners Raises Target Price to $45 From $39
Halozyme Therapeutics Inc (HALO) (Q1 2024) Earnings Call Transcript Highlights: Robust Growth ...
Halozyme Therapeutics Q1 2024 Earnings: Misses EPS Estimates but Shows Revenue Growth
Express News | Halozyme Therapeutics Shares Are Trading Higher Following Mixed Q1 Results
Express News | Halozyme Reiterates FY24 Guidance: Sees Total Revenue $915M-$985M Vs $951.47M Est., Adj. EPS $3.55-$3.90 Vs $3.68 Est